These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11910830)

  • 1. [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910830
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate].
    Mori M; Takahashi S
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):39-46. PubMed ID: 23842227
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
    Studney D
    Can J Cardiol; 2002 May; 18 Suppl A():3A-6A. PubMed ID: 12045787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
    Ann Intern Med; 2003 Apr; 138(7):I43. PubMed ID: 12667050
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
    MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
    Ruggenenti P; Remuzzi G
    Nat Clin Pract Nephrol; 2006 May; 2(5):250-1. PubMed ID: 16932436
    [No Abstract]   [Full Text] [Related]  

  • 8. Losartan: the first angiotensin receptor antagonist in clinical use.
    Beevers DG
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S1. PubMed ID: 8583475
    [No Abstract]   [Full Text] [Related]  

  • 9. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
    Gartenmann AC; Fossali E; von Vigier RO; Simonetti GD; Schmidtko J; Edefonti A; Bianchetti MG
    Kidney Int; 2003 Oct; 64(4):1450-4. PubMed ID: 12969165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin-II receptor blockers].
    Metelitsa VI
    Ter Arkh; 1996; 68(8):64-7. PubMed ID: 9019837
    [No Abstract]   [Full Text] [Related]  

  • 13. [The medicine of the month. Losartan (Cozaar)].
    Scheen AJ
    Rev Med Liege; 1997 May; 52(5):367-9. PubMed ID: 9273640
    [No Abstract]   [Full Text] [Related]  

  • 14. A clinical trial in type 2 diabetic nephropathy.
    Lewis EJ; Hunsicker LG; Rodby RA;
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
    Ruilope LM
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evidence based treatment of diabetic nephropathy].
    Sugimoto T
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():294-300. PubMed ID: 12430244
    [No Abstract]   [Full Text] [Related]  

  • 17. [Angiotensin II antagonists: a distinct therapeutic class].
    Waeber B; Brunner HR
    Presse Med; 1996 Oct; 25(32):1533-5. PubMed ID: 8952659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor blockers and nephropathy trials.
    Bloomgarden ZT
    Diabetes Care; 2001 Oct; 24(10):1834-8. PubMed ID: 11574450
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Ceriello A; Motz E
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873779
    [No Abstract]   [Full Text] [Related]  

  • 20. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
    Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
    Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.